CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities

CG Oncology Inc. (NASDAQ:CGON) is one of the best 52-week high stocks to buy right now. On November 24, analysts at Truist Securities initiated coverage of CG Oncology Inc. (NASDAQ:CGON) with a Buy rating and a $62 price target. The positive stance comes as the research firm remains optimistic about the company’s Biologics License Application for its lead product Creto. While the application began in the fourth quarter, there is a higher prospect of the drug being approved in 2026.

Initiating the BKLA submission affirms management’s firm belief that the candidate product will gain regulatory approval. The research firm has echoed the company’s readiness for manufacturing and launch in non-muscle invasive bladder cancer. There are also potential expansion opportunities for Creto, which could enhance commercial opportunities for the CG oncology lead product.

In other news, CG Oncology announced on November 26 that Christina Rossi will join its Board of Directors, replacing Simone Song of ORI Capital, who stepped down after more than ten years with the company. Rossi has held senior roles at Sanofi Genzyme and Biogen and holds degrees from Duke and Harvard.

Her appointment comes as CG Oncology works toward a BLA submission for its investigational bladder cancer therapy, cretostimogene, which has been studied in more than 400 patients with non-muscle invasive bladder cancer. CEO Arthur Kuan noted that the team is preparing for a potential launch pending FDA approval, though the treatment is still under review.

CG Oncology, Inc. (NASDAQ:CGON) is a biopharmaceutical company focused on developing and commercializing novel, bladder-sparing immunotherapies for patients with urologic cancers, particularly bladder cancer.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.